Viscosalactone B, a natural LSD1 inhibitor, inhibits proliferation in vitro and in vivo against prostate cancer cells

[1]  Qiang Xu,et al.  Selective targeting of the androgen receptor-DNA binding domain by the novel antiandrogen SBF-1 and inhibition of the growth of prostate cancer cells , 2021, Investigational New Drugs.

[2]  Menghan Liu,et al.  Targeting LSD1 for acute myeloid leukemia (AML) treatment. , 2020, Pharmacological research.

[3]  Bing Ma,et al.  Arborinine, a potential LSD1 inhibitor, inhibits epithelial-mesenchymal transition of SGC-7901 cells and adriamycin-resistant gastric cancer SGC-7901/ADR cells , 2020, Investigational New Drugs.

[4]  Dean Anthony Lee,et al.  Scaffolding LSD1 Inhibitors Impair NK Cell Metabolism and Cytotoxic Function Through Depletion of Glutathione , 2020, Frontiers in Immunology.

[5]  Hyongjun Jeon,et al.  The MAO Inhibitor Tranylcypromine Alters LPS- and Aβ-Mediated Neuroinflammatory Responses in Wild-type Mice and a Mouse Model of AD , 2020, Cells.

[6]  Shreyans K. Jain,et al.  Small Molecule CDK Inhibitors for the Therapeutic Management of Cancer. , 2020, Current topics in medicinal chemistry.

[7]  T. Gourdin.  Recent progress in treating advanced prostate cancer. , 2020, Current opinion in oncology.

[8]  J. Encinar,et al.  The LSD1 inhibitor iadademstat (ORY-1001) targets SOX2-driven breast cancer stem cells: a potential epigenetic therapy in luminal-B and HER2-positive breast cancer subtypes , 2020, Aging.

[9]  P. Limonta,et al.  Natural Compounds in Prostate Cancer Prevention and Treatment: Mechanisms of Action and Molecular Targets , 2020, Cells.

[10]  S. Mohapatra,et al.  Withania Somnifera (Ashwagandha) and Withaferin A: Potential in Integrative Oncology , 2019, International journal of molecular sciences.

[11]  P. Sil,et al.  Natural products: An upcoming therapeutic approach to cancer. , 2019, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[12]  Takayoshi Suzuki,et al.  NCL1, A Highly Selective Lysine-Specific Demethylase 1 Inhibitor, Suppresses Castration-Resistant Prostate Cancer Growth via Regulation of Apoptosis and Autophagy , 2019, Journal of clinical medicine.

[13]  S. Amente,et al.  Expanding the Role of the Histone Lysine-Specific Demethylase LSD1 in Cancer , 2019, Cancers.

[14]  Huijun Zhao,et al.  Screening, identification of prostate cancer urinary biomarkers and verification of important spots , 2019, Investigational New Drugs.

[15]  S. Lowe,et al.  Histone Demethylase LSD1 is required for Germinal Center formation and BCL6-driven lymphomagenesis , 2018, Nature Immunology.

[16]  Takayoshi Suzuki,et al.  Drug Design Concepts for LSD1-Selective Inhibitors. , 2018, Chemical record.

[17]  R. DePinho,et al.  Genetics and biology of prostate cancer , 2018, Genes & development.

[18]  N. Ahmad,et al.  Prostate cancer chemoprevention by natural agents: Clinical evidence and potential implications. , 2018, Cancer letters.

[19]  P. Kantoff,et al.  Current treatment strategies for advanced prostate cancer , 2018, International journal of urology : official journal of the Japanese Urological Association.

[20]  R. Kypta,et al.  WNT signalling in prostate cancer , 2017, Nature Reviews Urology.

[21]  J. Holzbeierlein,et al.  Characterization of a novel p110β‐specific inhibitor BL140 that overcomes MDV3100‐resistance in castration‐resistant prostate cancer cells , 2017, The Prostate.

[22]  Shivendra V. Singh,et al.  Withania somnifera: From prevention to treatment of cancer. , 2016, Molecular nutrition & food research.

[23]  A. Hamid,et al.  Pharmacologic overview of Withania somnifera, the Indian Ginseng , 2015, Cellular and Molecular Life Sciences.

[24]  Q. Yan,et al.  High-throughput screening to identify inhibitors of lysine demethylases. , 2015, Epigenomics.

[25]  Xiuheng Liu,et al.  Relationship between LSD1 expression and E-cadherin expression in prostate cancer , 2015, International Urology and Nephrology.

[26]  Takayoshi Suzuki,et al.  NCL1, a highly selective lysine-specific demethylase 1 inhibitor, suppresses prostate cancer without adverse effect , 2014, Oncotarget.

[27]  K. Komatsu,et al.  Effects of Ashwagandha (roots of Withania somnifera) on neurodegenerative diseases. , 2014, Biological & pharmaceutical bulletin.

[28]  Shivendra V. Singh,et al.  Molecular Targets and Mechanisms of Cancer Prevention and Treatment by Withaferin A, A Naturally Occurring Steroidal Lactone , 2013, The AAPS Journal.

[29]  M. Gleave,et al.  A Novel Antiandrogen, Compound 30, Suppresses Castration-Resistant and MDV3100-Resistant Prostate Cancer Growth In Vitro and In Vivo , 2013, Molecular Cancer Therapeutics.

[30]  Yu Liang,et al.  A Novel Selective LSD1/KDM1A Inhibitor Epigenetically Blocks Herpes Simplex Virus Lytic Replication and Reactivation from Latency , 2013, mBio.

[31]  F. Lan,et al.  Regulation of LSD1 histone demethylase activity by its associated factors. , 2005, Molecular cell.

[32]  Yang Shi,et al.  Histone Demethylation Mediated by the Nuclear Amine Oxidase Homolog LSD1 , 2004, Cell.

[33]  James M. Roberts,et al.  CDK inhibitors: positive and negative regulators of G1-phase progression. , 1999, Genes & development.

[34]  P. Guest,et al.  Multiplex Analyses Using Real-Time Quantitative PCR. , 2017, Methods in molecular biology.